# Phase 2 colorectal cancer trials recruiting: 225 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 225 trials in phase 2 for colorectal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 colorectal cancer trials: 225 rows for $11.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/colorectal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 225
- Recruiting or not yet: 225
- Read on: November 19, 2026

## Trials

The 25 newest of 225, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941843 | Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer | Damanhour University | Phase 2 | Not yet recruiting | Colorectal Cancer, Chemotherapy-Induced Peripheral Neuropathy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941843) |
| November 17, 2026 | NCT07941310 | A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer | Korea University Anam Hospital | Phase 2 | Not yet recruiting | Metastatic Colorectal Cancer, EGFR Amplified Colorectal Cancer | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941310) |
| November 16, 2026 | NCT07938021 | HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC) | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938021) |
| November 16, 2026 | NCT07937696 | A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Colorectal Carcinoma, EPCAM Lynch Syndrome, Lynch Syndrome, MLH1 Lynch Syndrome, MSH2 Lynch Syndrome, MSH6 Lynch... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937696) |
| November 9, 2026 | NCT07926477 | Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Colorectal Cancer | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926477) |
| November 3, 2026 | NCT07913906 | Alberta Cancer Exercise Dose in Colorectal Cancer | University of Calgary | Phase 2 | Not yet recruiting | Cancer, Colorectal Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913906) |
| October 27, 2026 | NCT07896681 | Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Colorectal Cancer (CRC) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896681) |
| October 26, 2026 | NCT07896096 | Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or... | Renmin Hospital of Wuhan University | Phase 2 | Recruiting | Refractory Metastatic Colorectal Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896096) |
| October 20, 2026 | NCT07884188 | Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer | Fudan University | Phase 2 | Recruiting | Metastatic Colorectal Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884188) |
| October 15, 2026 | NCT07875465 | Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic, Solid Tumors | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875465) |
| September 16, 2026 | NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After... | Incyte Corporation | Phase 2 | Recruiting | CRC (Colorectal Cancer) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823322) |
| September 11, 2026 | NCT07814417 | A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation | Eli Lilly and Company | Phase 2 | Not yet recruiting | Colorectal Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814417) |
| September 9, 2026 | NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With... | Vividion Therapeutics, Inc. | Phase 2 | Recruiting | Colorectal Adenocarcinoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811193) |
| September 9, 2026 | NCT07809893 | Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients | Sun Yat-sen University | Phase 2 | Recruiting | Colorectal Cancer | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809893) |
| August 27, 2026 | NCT07789210 | A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally... | Zhejiang University | Phase 2 | Recruiting | Colorectal Cancer, BRAF V600E Mutation Positive, Encorafenib, Cetuximab N01 | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789210) |
| July 27, 2026 | NCT07728019 | Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | CRC (Colorectal Cancer) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728019) |
| July 24, 2026 | NCT07724223 | Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Metastatic Colorectal Cancer (CRC) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724223) |
| July 22, 2026 | NCT07718490 | Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Metastatic Colorectal Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718490) |
| July 20, 2026 | NCT07714447 | Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer | Sun Yat-sen University | Phase 2 | Not yet recruiting | CRC (Colorectal Cancer), BRAF | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714447) |
| July 14, 2026 | NCT07702292 | \[68Ga\]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Blue Earth Diagnostics | Phase 2 | Recruiting | Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC), Invasive... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702292) |
| July 9, 2026 | NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Not yet recruiting | Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691489) |
| June 23, 2026 | NCT07662031 | Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer | Washington University School of Medicine | Phase 2 | Not yet recruiting | Colorectal Cancer, Metastatic Colorectal Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662031) |
| June 22, 2026 | NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Verastem, Inc. | Phase 2 | Recruiting | Colorectal Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659795) |
| June 18, 2026 | NCT07656766 | Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer | Peking University People's Hospital | Phase 2 | Not yet recruiting | Advanced Colorectal Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656766) |
| June 12, 2026 | NCT07644286 | A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Colorectal Cancer (CRC) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644286) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 16 |
| Sun Yat-sen University | 15 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 5 |
| M.D. Anderson Cancer Center | 5 |
| National Cancer Institute (NCI) | 5 |
| UNICANCER | 4 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| National Cancer Institute, Naples | 3 |
| Mayo Clinic | 3 |
| Federation Francophone de Cancerologie Digestive | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| Zhejiang University | 3 |
| Jiangsu Cancer Institute & Hospital | 2 |
| Peking University People's Hospital | 2 |
| Huazhong University of Science and Technology | 2 |
| Zealand University Hospital | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Shanghai Changzheng Hospital | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| Gruppo Oncologico del Nord-Ovest | 2 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 |
| University of California, Irvine | 2 |
| The First Hospital of Jilin University | 2 |

## By country

| Country | Trials |
| --- | --- |
| China | 99 |
| United States | 59 |
| France | 18 |
| Italy | 16 |
| Spain | 15 |
| Canada | 11 |
| Germany | 8 |
| Denmark | 6 |
| Japan | 6 |
| South Korea | 6 |
| Taiwan | 6 |
| United Kingdom | 5 |
| Australia | 4 |
| Switzerland | 4 |
| Netherlands | 4 |
| Brazil | 3 |
| Russia | 3 |
| Puerto Rico | 3 |
| Singapore | 3 |
| Turkey (Türkiye) | 3 |
| Czechia | 3 |
| Belgium | 2 |
| Austria | 2 |
| Poland | 2 |
| Israel | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
- [Advertising agencies in the United States](https://specstream.ai/data/businesses/advertising-agencies/united-states)
- [Logging contractors in the United States](https://specstream.ai/data/businesses/logging-contractors/united-states)
- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Dental hygiene clinics in the United States](https://specstream.ai/data/businesses/dental-hygiene-clinics/united-states)
